Takamichi Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takamichi Yamamoto has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Hideo Enoki
Department of Child Neurology, Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Naka-ku, Hamamatsu, Shizuoka, 430-8558, Japan
8 shared publications- Kensuke Kawai
Jichi Medical University Shimotsuke Japan
7 shared publications - Ayataka Fujimoto
Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, 2-12-12, Sumiyoshi, Naka-ku, Hamamatsu, Shizuoka 430-8558, Japan
6 shared publications - Ayataka Fujimoto
Center of Epilepsy and Functional Neurology Seirei Hamamatsu General Hospital Hamamatsu‐shi Japan
6 shared publications Ayataka Fujimoto
5 shared publicationsEunyeong Choe
SK Biopharmaceuticals Co., Ltd., Seongnam, Republic of Korea
5 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (6) , 3795-3813
Long-Term Efficacy of Adjunctive Cenobamate by Focal Seizure Subtypes: Open-Label Extension of a Randomized Clinical Study in a Multinational Asian Population
- 3 November 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (6) , 3795-3813
Open AccessLong-Term Efficacy of Adjunctive Cenobamate by Focal Seizure Subtypes: Open-Label Extension of a Randomized Clinical Study in a Multinational Asian Population
- Open Access
Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population
Objective: This study was undertaken to assess long‐term efficacy, safety, and tolerability of adjunctive cenobamate in an open‐label extension (OLE) of a randomized, double‐blind, placebo‐controlled, dose–response study (NCT04557085; YKP3089C035 [Study C035]) in Asian patients with uncontrolled focal seizures. Methods: Patients 18–70 years old with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications who completed the 24‐week double‐blind treatment period ( n = 425) at cenobamate doses of 100, 200, or 400 mg/day or placebo could enter a 52‐week OLE. All patients were converted to a cenobamate dose of 400 mg/day during a 20‐week double‐blind conversion phase and then entered a 32‐week open‐label maintenance phase at a starting dose of 300 mg/day. Results: Among the 410 patients who entered the double‐blind conversion phase, 357 (263 and 94 originally randomized to cenobamate and placebo, respectively) entered the OLE maintenance phase. The median percent focal seizure frequency reduction from double‐blind baseline for patients who received at least one dose of cenobamate during the 32‐week maintenance phase was 83.6%. The percent of patients achieving ≥50% and 100% responses during the maintenance phase was 75.1% and 25.5%, respectively. Among patients entering the OLE, 84.6% (347/410) completed the 52 weeks of treatment with cenobamate. The most commonly occurring treatment‐emergent adverse events (TEAEs) during the entire OLE were dizziness, somnolence, γ‐glutamyl transferase (GGT) increase, and COVID‐19 infection. GGT increase was not associated with any clinically significant findings. Serious TEAEs occurred in 11.7% of patients (48/410). There were no deaths and no cases of DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome reported. Significance: The high long‐term seizure frequency reductions, including a 100% responder rate of 25.5%, were consistent with previous long‐term cenobamate efficacy. The OLE safety profile was also generally consistent with the known cenobamate safety profile, with no new safety signals identified. These results support the use of cenobamate in adult Asian patients with uncontrolled focal seizures.
Open AccessLong‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population
Objective: This study was undertaken to assess long‐term efficacy, safety, and tolerability of adjunctive cenobamate in an open‐label extension (OLE) of a randomized, double‐blind, placebo‐controlled, dose–response study (NCT04557085; YKP3089C035 [Study C035]) in Asian patients with uncontrolled focal seizures. Methods: Patients 18–70 years old with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications who completed the 24‐week double‐blind treatment period ( n = 425) at cenobamate doses of 100, 200, or 400 mg/day or placebo could enter a 52‐week OLE. All patients were converted to a cenobamate dose of 400 mg/day during a 20‐week double‐blind conversion phase and then entered a 32‐week open‐label maintenance phase at a starting dose of 300 mg/day. Results: Among the 410 patients who entered the double‐blind conversion phase, 357 (263 and 94 originally randomized to cenobamate and placebo, respectively) entered the OLE maintenance phase. The median percent focal seizure frequency reduction from double‐blind baseline for patients who received at least one dose of cenobamate during the 32‐week maintenance phase was 83.6%. The percent of patients achieving ≥50% and 100% responses during the maintenance phase was 75.1% and 25.5%, respectively. Among patients entering the OLE, 84.6% (347/410) completed the 52 weeks of treatment with cenobamate. The most commonly occurring treatment‐emergent adverse events (TEAEs) during the entire OLE were dizziness, somnolence, γ‐glutamyl transferase (GGT) increase, and COVID‐19 infection. GGT increase was not associated with any clinically significant findings. Serious TEAEs occurred in 11.7% of patients (48/410). There were no deaths and no cases of DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome reported. Significance: The high long‐term seizure frequency reductions, including a 100% responder rate of 25.5%, were consistent with previous long‐term cenobamate efficacy. The OLE safety profile was also generally consistent with the known cenobamate safety profile, with no new safety signals identified. These results support the use of cenobamate in adult Asian patients with uncontrolled focal seizures.
- Open Access
Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population
Objective: To examine early responses to cenobamate therapy using prospective data from a dose–response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day. Methods: In Study C035, adults 18–70 years of age with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications were randomized 1:1:1:1 to receive placebo or adjunctive cenobamate 100, 200, or 400 mg/day. The 24‐week double‐blind study included an 18‐week titration and 6‐week maintenance phase. During the first 8 weeks of titration (“early titration phase”), all cenobamate patients received the same dosing regimen: 12.5 mg/day for 2 weeks, 25 mg/day for 2 weeks, 50 mg/day for 2 weeks, and 100 mg/day for 2 weeks. Change in seizure frequency from baseline and responder rates were assessed at these 2‐week intervals for combined cenobamate dose groups vs placebo. Analyses were performed on the modified intent‐to‐treat maintenance (MITT‐M) population (≥1 study drug dose and seizure data in the maintenance phase); all patients completed early titration. Results: Of 519 patients randomized, 446 were included in the MITT‐M population (placebo n = 117, cenobamate n = 329). During Weeks 1–2, 3–4, 5–6, and 7–8 of titration, cenobamate patients experienced a median reduction in 28‐day seizure frequency of 16.0% (vs 20.0% placebo, p = .81), 27.3% (vs 22.2% placebo, p = .42), 42.9% (vs 15.4% placebo, p = .002), and 55.6% (vs 20.0% placebo, p < .001), respectively. During Weeks 5–6 and 7–8, the 100% responder rates for cenobamate 50 and 100 mg/day were 17.0% (vs 12.8% placebo, p = .29) and 26.7% (vs 8.5% placebo, p < .001), respectively. Significance: Statistically significant responses to cenobamate treatment occurred within the first 8 weeks of titration, including a 42.9% median reduction in 28‐day seizure frequency (Weeks 5–6) and a seizure‐free rate of 26.7% (Weeks 7–8). These data show that substantial seizure reductions occurred in many patients early during cenobamate titration.
Open AccessEarly response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population
Objective: To examine early responses to cenobamate therapy using prospective data from a dose–response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day. Methods: In Study C035, adults 18–70 years of age with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications were randomized 1:1:1:1 to receive placebo or adjunctive cenobamate 100, 200, or 400 mg/day. The 24‐week double‐blind study included an 18‐week titration and 6‐week maintenance phase. During the first 8 weeks of titration (“early titration phase”), all cenobamate patients received the same dosing regimen: 12.5 mg/day for 2 weeks, 25 mg/day for 2 weeks, 50 mg/day for 2 weeks, and 100 mg/day for 2 weeks. Change in seizure frequency from baseline and responder rates were assessed at these 2‐week intervals for combined cenobamate dose groups vs placebo. Analyses were performed on the modified intent‐to‐treat maintenance (MITT‐M) population (≥1 study drug dose and seizure data in the maintenance phase); all patients completed early titration. Results: Of 519 patients randomized, 446 were included in the MITT‐M population (placebo n = 117, cenobamate n = 329). During Weeks 1–2, 3–4, 5–6, and 7–8 of titration, cenobamate patients experienced a median reduction in 28‐day seizure frequency of 16.0% (vs 20.0% placebo, p = .81), 27.3% (vs 22.2% placebo, p = .42), 42.9% (vs 15.4% placebo, p = .002), and 55.6% (vs 20.0% placebo, p < .001), respectively. During Weeks 5–6 and 7–8, the 100% responder rates for cenobamate 50 and 100 mg/day were 17.0% (vs 12.8% placebo, p = .29) and 26.7% (vs 8.5% placebo, p < .001), respectively. Significance: Statistically significant responses to cenobamate treatment occurred within the first 8 weeks of titration, including a 42.9% median reduction in 28‐day seizure frequency (Weeks 5–6) and a seizure‐free rate of 26.7% (Weeks 7–8). These data show that substantial seizure reductions occurred in many patients early during cenobamate titration.
- Open Access
A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures
Objectives: This randomized, double‐blind, placebo‐controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures. Methods: Adults 18–70 years of age with ≥8 seizures (focal aware motor, focal impaired awareness, or focal to bilateral tonic–clonic) during an 8‐week baseline, despite treatment with 1–3 antiseizure medications (ASMs), were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg/day. The study included an 18‐week titration phase and a 6‐week maintenance phase. The primary efficacy analysis was a hierarchical step‐down comparison of the percent change from baseline in 28‐day seizure frequency vs placebo during the maintenance phase for cenobamate 200, then 400, and then 100 mg/day. Results: Among 519 patients randomized, 446 received ≥1 dose of study drug and had ≥1 efficacy measure during the maintenance phase (placebo, n = 117; 100 mg/day, n = 113; 200 mg/day, n = 113; and 400 mg/day, n = 103). Median percent change in seizure frequency during the maintenance phase was −25.9% for placebo vs −42.6%, −78.3%, and −100% for cenobamate 100, 200, and 400 mg/day, respectively (all p 's < .001). During the 12‐week period encompassing the last 6 weeks of titration and the 6‐week maintenance phase (secondary outcome), the median percent change in seizure frequency was −20.1% for placebo vs −42.6%, −77.1%, and −89.2% for cenobamate 100, 200, and 400 mg/day, respectively. Seizure‐free rates during the maintenance phase were 2.6% of patients for placebo vs 12.4%, 30.1%, and 52.4% for cenobamate 100, 200, and 400 mg/day, respectively, and during the 12‐week period were 0.8% for placebo vs 8.5%, 19.7%, and 30.6% for the cenobamate groups. The most common treatment‐emergent adverse events in cenobamate patients (≥20%) were dose‐related dizziness and somnolence. Significance: Cenobamate 100, 200, and 400 mg/day reduced focal seizures in Asian patients in a dose‐related fashion and was generally well tolerated.
Open AccessA randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures
Objectives: This randomized, double‐blind, placebo‐controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures. Methods: Adults 18–70 years of age with ≥8 seizures (focal aware motor, focal impaired awareness, or focal to bilateral tonic–clonic) during an 8‐week baseline, despite treatment with 1–3 antiseizure medications (ASMs), were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg/day. The study included an 18‐week titration phase and a 6‐week maintenance phase. The primary efficacy analysis was a hierarchical step‐down comparison of the percent change from baseline in 28‐day seizure frequency vs placebo during the maintenance phase for cenobamate 200, then 400, and then 100 mg/day. Results: Among 519 patients randomized, 446 received ≥1 dose of study drug and had ≥1 efficacy measure during the maintenance phase (placebo, n = 117; 100 mg/day, n = 113; 200 mg/day, n = 113; and 400 mg/day, n = 103). Median percent change in seizure frequency during the maintenance phase was −25.9% for placebo vs −42.6%, −78.3%, and −100% for cenobamate 100, 200, and 400 mg/day, respectively (all p 's < .001). During the 12‐week period encompassing the last 6 weeks of titration and the 6‐week maintenance phase (secondary outcome), the median percent change in seizure frequency was −20.1% for placebo vs −42.6%, −77.1%, and −89.2% for cenobamate 100, 200, and 400 mg/day, respectively. Seizure‐free rates during the maintenance phase were 2.6% of patients for placebo vs 12.4%, 30.1%, and 52.4% for cenobamate 100, 200, and 400 mg/day, respectively, and during the 12‐week period were 0.8% for placebo vs 8.5%, 19.7%, and 30.6% for the cenobamate groups. The most common treatment‐emergent adverse events in cenobamate patients (≥20%) were dose‐related dizziness and somnolence. Significance: Cenobamate 100, 200, and 400 mg/day reduced focal seizures in Asian patients in a dose‐related fashion and was generally well tolerated.
- Open Access
- 30 September 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 133, 43-51
Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population
- 30 September 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 133, 43-51
Open AccessEfficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population
- Open Access
- 25 August 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 171, 110651
Effectiveness and safety of perampanel by concomitant antiseizure medications: Insights from the real-world PERMIT Extension study
- 25 August 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 171, 110651
Open AccessEffectiveness and safety of perampanel by concomitant antiseizure medications: Insights from the real-world PERMIT Extension study
- Open Access
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Clinical factors associated with perampanel retention, response, seizure freedom and tolerability: real-world evidence from the PERMIT Extension study
Background: Perampanel (PER) is effective in treating focal and generalised seizures. The PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) Extension study was a large, pooled analysis of PER clinical practice studies that assessed the effectiveness and safety/tolerability of PER in over 6800 people with epilepsy. Objectives: To determine clinical factors associated with PER retention, response, seizure freedom and tolerability when used in clinical practice. Design: An exploratory post hoc analysis of data from all individuals included in PERMIT Extension. Methods: Univariate and multivariable logistic regression analyses were performed to identify baseline factors associated with retention rate, responder rate (⩾50% seizure frequency reduction), seizure freedom rate (no seizures since at least the previous visit) and incidence of adverse events (AEs). Results: A total of 6822 people with epilepsy treated with PER were included. Baseline factors associated with retention were absence of psychiatric comorbidity (odds ratio [95% confidence interval], 1.99 [1.403–2.825]; p < 0.001), fewer focal seizures (1.01 [1.004–1.014]; p < 0.001) and fewer previous antiseizure medications (ASMs; 1.06 [1.013–1.119]; p = 0.013). Factors associated with response were absence of focal seizures (2.12 [1.532–2.924]; p < 0.001), fewer previous ASMs (1.19 [1.136–1.250]; p < 0.001) and absence of concomitant sodium channel blocker (SCB) ASM(s) (1.96 [1.455–2.628]; p < 0.001). Factors associated with seizure freedom were fewer total seizures (1.04 [1.020–1.061]; p < 0.001), absence of focal seizures (3.45 [2.387–4.979]; p < 0.001), fewer previous ASMs (1.11 [1.028–1.205]; p = 0.008), absence of concomitant SCB ASM(s) (1.46 [1.051–2.028]; p = 0.024) and absence of concomitant gamma-aminobutyric acid (GABA)-ergic ASM(s) (2.08 [1.266–3.412]; p = 0.004). Factors associated with occurrence of AEs were older age (1.01 [1.006–1.015]; p < 0.001), longer epilepsy duration (1.01 [1.010–1.012]; p = 0.044), presence of psychiatric comorbidity (1.74 [1.469–2.062]; p < 0.001) and greater number of previous ASMs (1.09 [1.069–1.119]; p < 0.001). Conclusion: This study identified clinical factors associated with PER’s real-world effectiveness and tolerability, which may help inform treatment decisions in clinical practice.
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Open AccessClinical factors associated with perampanel retention, response, seizure freedom and tolerability: real-world evidence from the PERMIT Extension study
Background: Perampanel (PER) is effective in treating focal and generalised seizures. The PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) Extension study was a large, pooled analysis of PER clinical practice studies that assessed the effectiveness and safety/tolerability of PER in over 6800 people with epilepsy. Objectives: To determine clinical factors associated with PER retention, response, seizure freedom and tolerability when used in clinical practice. Design: An exploratory post hoc analysis of data from all individuals included in PERMIT Extension. Methods: Univariate and multivariable logistic regression analyses were performed to identify baseline factors associated with retention rate, responder rate (⩾50% seizure frequency reduction), seizure freedom rate (no seizures since at least the previous visit) and incidence of adverse events (AEs). Results: A total of 6822 people with epilepsy treated with PER were included. Baseline factors associated with retention were absence of psychiatric comorbidity (odds ratio [95% confidence interval], 1.99 [1.403–2.825]; p < 0.001), fewer focal seizures (1.01 [1.004–1.014]; p < 0.001) and fewer previous antiseizure medications (ASMs; 1.06 [1.013–1.119]; p = 0.013). Factors associated with response were absence of focal seizures (2.12 [1.532–2.924]; p < 0.001), fewer previous ASMs (1.19 [1.136–1.250]; p < 0.001) and absence of concomitant sodium channel blocker (SCB) ASM(s) (1.96 [1.455–2.628]; p < 0.001). Factors associated with seizure freedom were fewer total seizures (1.04 [1.020–1.061]; p < 0.001), absence of focal seizures (3.45 [2.387–4.979]; p < 0.001), fewer previous ASMs (1.11 [1.028–1.205]; p = 0.008), absence of concomitant SCB ASM(s) (1.46 [1.051–2.028]; p = 0.024) and absence of concomitant gamma-aminobutyric acid (GABA)-ergic ASM(s) (2.08 [1.266–3.412]; p = 0.004). Factors associated with occurrence of AEs were older age (1.01 [1.006–1.015]; p < 0.001), longer epilepsy duration (1.01 [1.010–1.012]; p = 0.044), presence of psychiatric comorbidity (1.74 [1.469–2.062]; p < 0.001) and greater number of previous ASMs (1.09 [1.069–1.119]; p < 0.001). Conclusion: This study identified clinical factors associated with PER’s real-world effectiveness and tolerability, which may help inform treatment decisions in clinical practice.
- Open Access
- 20 December 2024
- Published by Elsevier in Epilepsy Research
- Vol. 210, 107494
Long-term efficacy and safety of perampanel monotherapy in patients with newly diagnosed or currently untreated recurrent focal-onset seizures: Results from the open-label extension phase of FREEDOM (Study 342)
- 20 December 2024
- Published by Elsevier in Epilepsy Research
- Vol. 210, 107494
Open AccessLong-term efficacy and safety of perampanel monotherapy in patients with newly diagnosed or currently untreated recurrent focal-onset seizures: Results from the open-label extension phase of FREEDOM (Study 342)
- Open Access
- 12 January 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (1) , 135
Unexplained Progressive Neurological Deficits after Corpus Callosotomy May Be Caused by Autoimmune Encephalitis: A Case of Suspected Postoperative Anti-NMDAR Encephalitis
The main causes of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis are ovarian teratoma and herpes simplex virus (HSV) encephalitis. We present a rare case of suspected anti-NMDAR encephalitis caused by corpus callosotomy (CC). An 18-year-old woman with Lennox-Gastaut syndrome underwent CC. Although left hemiplegic due to cerebral hemorrhage and impaired consciousness due to cerebral venous sinus thrombosis (CVST) appeared postoperatively, anticoagulant therapy quickly improved CVST and impaired consciousness. However, various unexplained symptoms such as insomnia, hallucination, impulsivity, impaired consciousness, and a new type of drug-resistant cluster seizures gradually developed over a 2-month period. Magnetic resonance imaging revealed the gradual extension of a hyperintense area from the right frontal lobe on fluid-attenuated inversion recovery images. Intravenous methylprednisolone pulse was initiated from postoperative day (POD) 74, followed by intravenous immunoglobulin (IVIg) therapy, although white blood cell counts were normal in all three cerebrospinal fluid (CSF) examinations. After IVIg therapy, the above unexplained symptoms promptly improved. On POD 103, antibodies against NMDAR were revealed in both the serum and CSF collected before these immunotherapies. The patient was transferred to a rehabilitation hospital due to residual left hemiplegia. Psychiatric symptoms and a new onset of drug-resistant seizures may be suggestive of postoperative anti-NMDAR encephalitis, even if CSF findings are mild.
- 12 January 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (1) , 135
Open AccessUnexplained Progressive Neurological Deficits after Corpus Callosotomy May Be Caused by Autoimmune Encephalitis: A Case of Suspected Postoperative Anti-NMDAR Encephalitis
The main causes of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis are ovarian teratoma and herpes simplex virus (HSV) encephalitis. We present a rare case of suspected anti-NMDAR encephalitis caused by corpus callosotomy (CC). An 18-year-old woman with Lennox-Gastaut syndrome underwent CC. Although left hemiplegic due to cerebral hemorrhage and impaired consciousness due to cerebral venous sinus thrombosis (CVST) appeared postoperatively, anticoagulant therapy quickly improved CVST and impaired consciousness. However, various unexplained symptoms such as insomnia, hallucination, impulsivity, impaired consciousness, and a new type of drug-resistant cluster seizures gradually developed over a 2-month period. Magnetic resonance imaging revealed the gradual extension of a hyperintense area from the right frontal lobe on fluid-attenuated inversion recovery images. Intravenous methylprednisolone pulse was initiated from postoperative day (POD) 74, followed by intravenous immunoglobulin (IVIg) therapy, although white blood cell counts were normal in all three cerebrospinal fluid (CSF) examinations. After IVIg therapy, the above unexplained symptoms promptly improved. On POD 103, antibodies against NMDAR were revealed in both the serum and CSF collected before these immunotherapies. The patient was transferred to a rehabilitation hospital due to residual left hemiplegia. Psychiatric symptoms and a new onset of drug-resistant seizures may be suggestive of postoperative anti-NMDAR encephalitis, even if CSF findings are mild.
- Open Access
- 21 September 2022
- Published by Elsevier in Epilepsy & Behavior
- Vol. 136, 108885
Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence
- 21 September 2022
- Published by Elsevier in Epilepsy & Behavior
- Vol. 136, 108885
Open AccessPerampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence